Nektar will test its experimental drug, NKTR-214, in combination with Bristol-Myers’ best-selling cancer drugs Opdivo and Yervoy. Research will focus on 20 cancer indications across nine different tumor types, ranging from melanoma to lung cancers.
Through the deal, Nektar is eligible to achieve an additional $1.78 billion in regulatory and sales milestone payments from Bristol-Myers. If the FDA approves NKTR-214, Nektar and Bristol-Myers would split global profits by 65 percent and 35 percent, respectively.
The companies expect to finalize the transaction in the second quarter of 2018.
More articles on supply chain:
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
Amazon pushes to become a major hospital supplier: 7 things to know
Walgreens is reportedly in talks to purchase AmerisourceBergen: 7 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.